CClinicalTrials.gg
Sign In
Status unknownNCT01264640Updated Dec 22, 2010

Anti-Platelet Drugs and Brain-derived Neurotrophic Factor (BDNF) in Human Serum and Plasma

An interventional study of Aspirin and Clopidogrel in Healthy Volunteers, sponsored by University of Rostock. Status unknown at 1 site in Germany. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-12-22.

Sponsored by University of Rostock · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Jul 2010), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The impact of anti-platelet drugs on the concentrations of Brain-derived neurotrophic factor (BDNF) in human plasma and serum is unknown. It is the aim of this study to investigate the impact of a single dose of Aspirin (500 mg) or Clopdigrel (600 mg) on the concentrations of Brain-derived neurotrophic factor (BDNF) in plasma and serum of healthy volunteers.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Brain-derived neurotrophic factor (BDNF)
  • Platelets
  • Aspirin
  • Clopidogrel
03

In context

Lead sponsor

University of Rostock is the lead sponsor of 46 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 18-50 years
  • Gender: Male

Exclusion criteria

Exclusion Criteria:

  • Any acute disease
  • Any chronic disease
  • Any medication
  • Allergies / Intolerance in association with Aspirin or Clopidogrel
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    A

    Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).

    Drug: Aspirin and Clopidogrel

Interventions

  • DrugAspirin and Clopidogrel

    Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Blood collection for the measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).

06

What researchers measure

Primary outcomes

  1. BDNF plasma and serum concentration 24 hours after Aspirin or Clopidgrel intake

    Time frame: 24 hours

Secondary outcomes

  1. 5-HT and TGF-beta concentrations 24 hours after Aspirin or Clopidgrel intake

    Time frame: 24 hours

07

Study locations

1 site
  • Dep. of Pneumology, University of Rostock
    Rostock, Mecklenburg-Vorpommern 18057, Germany
08

References and documents

Publications

  • Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, Virchow JC. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging. 2005 Jan;26(1):115-23. doi: 10.1016/j.neurobiolaging.2004.03.002. PubMed 15585351 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 22, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01264640
Lead sponsor
University of Rostock
First posted
Dec 22, 2010
Start date
Jul 2010
Primary completion
Feb 2011 (estimated)
Completion
Mar 2011 (estimated)
Last update
Dec 22, 2010

Study contacts

Marek Lommatzsch, PD Dr.
principal investigator · University of Rostock

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

University of Rostock

Start the discussion